Direct conversion of human fibroblasts to multilineage blood progenitors
Direct conversion of human fibroblasts to multilineage blood progenitors# Biology - 生物学
j*e
1 楼
rt 回答的好有包子
h*y
2 楼
Scientists turn human skin into blood Scientists at McMaster University have discovered how to make human blood from adult human skin. The discovery could mean that people needing blood for surgery, cancer treatment or treatment of blood conditions like anemia will be able to have blood created from a patch of their own skin to provide transfusions. Clinical trials could begin as soon as 2012. The researchers have also shown that the conversion is direct. Making blood from skin does not require the middle step of changing a skin stem cell into a pluripotent stem cell that could make many other types of human cells, then turning it into a blood stem cell. The discovery was replicated several times over two years using human skin from both young and old people to prove it works for any age of person. Citation: Eva Szabo, Shravanti Rampalli, Ruth M. Risueño, Angelique Schnerch, Ryan Mitchell, Aline Fiebig-Comyn, Marilyne Levadoux-Martin, Mickie Bhatia, 'Direct conversion of human fibroblasts to multilineage blood progenitors', Nature November 7th 2010 doi:10.1038/nature09591 Abstract: As is the case for embryo-derived stem cells, application of reprogrammed human induced pluripotent stem cells is limited by our understanding of lineage specification. Here we demonstrate the ability to generate progenitors and mature cells of the haematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. Ectopic expression of OCT4 (also called POU5F1)-activated haematopoietic transcription factors, together with specific cytokine treatment, allowed generation of cells expressing the pan-leukocyte marker CD45. These unique fibroblast-derived cells gave rise to granulocytic, monocytic, megakaryocytic and erythroid lineages, and demonstrated in vivo engraftment capacity. We note that adult haematopoietic programs are activated, consistent with bypassing the pluripotent state to generate blood fate: this is distinct from haematopoiesis involving pluripotent stem cells, where embryonic programs are activated. These findings demonstrate restoration of multipotency from human fibroblasts, and suggest an alternative approach to cellular reprogramming for autologous cell-replacement therapies that avoids complications associated with the use of human pluripotent stem cells.
Within few years, scientists should be able to convert fell fates as they wish.
S*I
5 楼
只要签证上没加注就可以。
【在 j**e 的大作中提到】 : rt 回答的好有包子
n*k
6 楼
the iPS hypo still not done yet...although researches along this line are very much valuable...I think the next going to be direct F- to any without any factors....
【在 a****d 的大作中提到】 : Within few years, scientists should be able to convert fell fates as they : wish.
j*e
7 楼
他是在visa上面的annotation上面加注吗?
【在 S**I 的大作中提到】 : 只要签证上没加注就可以。
b*l
8 楼
MEF 的 piPS 已经做成了吧。
they
【在 n********k 的大作中提到】 : the iPS hypo still not done yet...although researches along this line are : very much valuable...I think the next going to be direct F- to any without : any factors....
S*I
9 楼
是
【在 j**e 的大作中提到】 : 他是在visa上面的annotation上面加注吗?
n*k
10 楼
?
【在 b*****l 的大作中提到】 : MEF 的 piPS 已经做成了吧。 : : they
J*a
11 楼
那最多三个月
【在 S**I 的大作中提到】 : 是
a*d
12 楼
You are right, iPSCs hypo is still there. It's just such a crowded field now and people are going nuts to compete for publishing.People from out lab just found almost identical xx cell derived iPCSs results being published. Those disease iPSCs models will continue to water on top journals for sure. Along with that, reprogramming becomes hotter and hotter. For the next few years, people still have to rely on TFs for reprogramming. Large small molecular screening is on the way to replace those TFs ultimately, but won't be that easy form my point of view. Even though we can make iPSCs or reprogram cell types, it's still a long way to go for clinical propose. Maybe blood system related treatment can benefit from those study first since the transplantation works so well for blood system. But for other parts of the body, especially central nervous system, I won't foresee any application from iPSCs or reprogramming cells in next few years.Geron's hESC clinical trial will tell more about cell transplantation for CNS disease treatment, and how difficult it will be.
【在 n********k 的大作中提到】 : the iPS hypo still not done yet...although researches along this line are : very much valuable...I think the next going to be direct F- to any without : any factors....